From: Whiteside, Timothy <Timothy.Whiteside@shionogi.com>
Sent: Wednesday, November 7, 2018 4:04 PM
To: AGO - High Cost Prescription Drugs
Subject: New Prescription Drug Notification

To whom it may concern:

This is to inform you that Shionogi Inc. recently introduced Mulpleta® (lusutrombopag tablets) (NDC 59630-551-07) into the U.S. commercial market. The first shipment of Mulpleta® to customers occurred on September 5, 2018. It has recently come to our attention that Shionogi inadvertently did not provide notification of Mulpleta®'s commercial release to the Vermont Attorney General.

The marketing plan used at the launch of Mulpleta® was to promote the drug using a small specialty salesforce focused on Hepatologists and Gastroenterologists who treat Thrombocytopenia (TCP) in Chronic Liver Disease (CLD) patients and perform a high volume of scheduled invasive procedures. In addition, Shionogi intends to contract with health plans and pharmacy benefit managers. The US WAC price was set at $8,500 per course of therapy. Mulpleta® is available for open distribution. Currently, Mulpleta® is only sold in Japan and the US. It was launched in Japan on December 1, 2015.

The estimated national volume of patients who might be prescribed Mulpleta® is not in the public domain or publicly available.

Mulpleta® was granted priority review by the FDA prior to final approval. It was not granted breakthrough therapy designation.

Mulpleta® was developed by Shionogi & Co., Ltd. and its affiliates.

Pursuant to 18 V.S.A. § 4637(d), the information provided herein is limited to that which is otherwise in the public domain or publicly available.

Please reply to confirm receipt.

Tim Whiteside
Director, Managed Markets Finance

SHIONOGI INC.
300 Campus Drive
Suite 300
Florham Park, NJ 07932

Phone: (973)307-3396